Compare HRTG & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HRTG | TBPH |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 898.0M | 824.9M |
| IPO Year | 2014 | 2013 |
| Metric | HRTG | TBPH |
|---|---|---|
| Price | $23.29 | $16.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $33.50 | $18.40 |
| AVG Volume (30 Days) | ★ 405.1K | 301.7K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 214.43 | ★ 279.13 |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $847,330,000.00 | $15,386,000.00 |
| Revenue This Year | $7.50 | $8.46 |
| Revenue Next Year | $6.74 | N/A |
| P/E Ratio | $18.93 | ★ N/A |
| Revenue Growth | ★ 3.71 | N/A |
| 52 Week Low | $16.83 | $9.10 |
| 52 Week High | $31.98 | $21.03 |
| Indicator | HRTG | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 37.19 | 45.74 |
| Support Level | $22.95 | $16.14 |
| Resistance Level | $28.55 | $17.21 |
| Average True Range (ATR) | 1.30 | 0.39 |
| MACD | -0.70 | -0.07 |
| Stochastic Oscillator | 23.13 | 11.83 |
Heritage Insurance Holdings Inc is a regional property and casualty insurance company that offers a variety of personal and commercial insurance products. Through its subsidiaries, Heritage Property & Casualty Insurance, Narragansett Bay Insurance, and Zephyr Insurance, the company issues personal residential property insurance in various states in the United States. It also offers commercial residential insurance predominantly for its Florida properties. Heritage Insurance manages insurance underwriting, customer services, actuarial analysis, distribution, and claims processing internally. Company operates in Alabama, California, Connecticut, Delaware, Florida, Georgia, Hawaii, Maryland, Massachusetts, Mississippi, New Jersey, New York, North Carolina, Rhode Island, South Carolina.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.